Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.
You may also be interested in...
Pfizer/Protalix’s Elelyso Offers Gaucher Patients A Vegetarian Option
Gaucher disease enzyme-replacement therapy Elelyso is the first FDA-approved plant-cell based recombinant therapeutic protein, a biosimilar option that may eliminate the production-related problems Genzyme’s Cerezyme and Shire’s Vpriv face with animal cell-based processes. Pfizer is launching Elelyso at a 25% discount to Cerezyme and promising to maintain a two-year supply.
FDA Delays Approval Of Protalix/Pfizer Gaucher Drug; Seeks More Data From Late-Stage Trials
FDA may be seeking more safety data before approving of Uplyso, a plant cell-derived enzyme replacement therapy.
FDA Delays Approval Of Protalix/Pfizer Gaucher Drug; Seeks More Data From Late-Stage Trials
FDA may be seeking more safety data before approving of Uplyso, a plant cell-derived enzyme replacement therapy.